However, its role in primary tumors of 258 breast cancer patients showed that around 44% of patients were HSD3B1 positive and knockdown of HSD3B1 inhibited both cell proliferation and cell migration irrespective of estrogen receptor action [40]. This evidence concerns the gene ESR1 and breast carcinoma.